E-Learning

Investing.com -- Canada’s main stock index opened down on Friday after U.S. President Donald Trump reignited fears of a U.S.-China trade war.

Investing.com -- Goldman Sachs has initiated coverage of diabetes technology stocks Insulet (NASDAQ:PODD) and Dexcom (NASDAQ:DXCM) with Buy ratings, citing strong long-term growth prospects in both the insulin delivery and continuous glucose monitoring (CGM) markets.

Is IONQ's rapid growth worth the risk, or does MSFT's stable cloud dominance make it the better quantum cloud buy today?

Early Foreign Exchange, New York prices.

Prices as of 10:00:19 AM Friday, May 30.

URA, DAPP, NIKL, BCOR and CHAT topped sector ETF gains in May, riding a broad market rebound on easing tariffs and strong tech earnings.

MRX, BIRK and DB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 30, 2025.

The mean of analysts' price targets for Xperi (XPER) points to a 134.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 32.1% in Janus International Group (JBI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.